In a Reversal, F.D.A. Requires Limits on Who Will get Alzheimer’s Drug
When the F.D.A. approved Aduhelm a month ago, its original label had said that the drug is “for the treatment of Alzheimer’s disease.” The surprisingly broad label caused a storm of concern among many Alzheimer’s experts, even those who had…